Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals. (Record no. 19958769)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01211 a2200325 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515231832.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201101s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2212-3911 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.2174/157488610792245993 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Büttel, Isabel C |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20110125 |
| 245 00 - TITLE STATEMENT | |
| Title | Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Current drug safety |
| Date of publication, distribution, etc. | Oct 2010 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 287-92 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Guideline; Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibody Formation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biological Products |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Approval |
| General subdivision | organization & administration |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Industry |
| General subdivision | organization & administration |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug-Related Side Effects and Adverse Reactions |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Legislation, Drug |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Marketing |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Risk Assessment |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Völler, Katrin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Schneider, Christian K |
| 773 0# - HOST ITEM ENTRY | |
| Title | Current drug safety |
| Related parts | vol. 5 |
| -- | no. 4 |
| -- | p. 287-92 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.2174/157488610792245993">https://doi.org/10.2174/157488610792245993</a> |
| Public note | Available from publisher's website |
No items available.